CLMT vs LEN · rev $4.19B vs rev $34.19B
Calumet Specialty Products Partners (CLMT) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
LEN (LEN) common stock.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
CLMT currently screens at market cap $2.89B. LEN currently screens at market cap $0.
Not investment advice. Open the CLMT and LEN stock pages for the full models.
Not investment advice.